文献速递乳腺癌

CBCSG006 试验生物标志物评估:顺铂联合吉西他滨对比紫杉醇联合吉西他滨一线治疗转移性三阴性乳腺癌的随机 III 期研究

Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

CBCSG006 试验显示,顺铂联合吉西他滨(GP)方案一线治疗转移性三阴性乳腺癌(mTNBC)的疗效优于紫杉醇联合吉西他滨(GT)方案。本研究更新生存数据并探索疗效生物标志物,发现 HR 缺陷(含 gBRCA1/2 突变)与 GP 方案更优的无进展生存(PFS)和客观缓解率(ORR)显著相关,而 PD-L1 状态与疗效无显著交互作用。

要点

  • GP 方案较 GT 方案显著改善 mTNBC 患者的中位 PFS(7.73 个月 vs 6.07 个月,P=0.005)。
  • HR 缺陷状态与 GP 方案更高的 ORR 和更长的 PFS 显著相关(ORR 71.9% vs 38.7%,P=0.008;PFS 10.37 vs 4.30 个月,P=0.011)。
  • gBRCA1/2 突变与治疗对 PFS 无显著交互作用,PD-L1 状态与疗效无显著关联。

核心结论

  • GP 方案一线治疗 mTNBC 的疗效优于 GT 方案,HR 缺陷(含 gBRCA1/2 突变)可能是顺铂为基础方案疗效更优的生物标志物。
  • 基于复合风险的 STEPP 分析显示,低复合风险患者从 GP 方案获得的 PFS 绝对获益更大。

研究设计与样本

  • CBCSG006 是一项随机 III 期试验,比较 GP 与 GT 方案一线治疗 mTNBC。
  • 胚系 HR 面板(含 BRCA1/2)突变在 55.9%(132/236)患者中评估,PD-L1 表达在 48.3%(114/236)患者中评估。
  • 采用非参数滑动窗口 STEPP 方法分析绝对生存获益,所有统计检验为双侧。

主要发现

  • GP 组中位 PFS 为 7.73 个月(95%CI 6.46-9.00),GT 组为 6.07 个月(95%CI 5.32-6.83),P=0.005;总生存(OS)无显著差异。
  • HR 状态与治疗对 PFS 存在显著交互作用;HR 缺陷患者在 GP 组的 ORR 为 71.9% vs GT 组 38.7%(P=0.008),中位 PFS 为 10.37 vs 4.30 个月(P=0.011)。
  • gBRCA1/2 状态与治疗对 PFS 无显著交互作用;gBRCA1/2 突变患者在 GP 组 ORR 数值更高(83.3% vs 37.5%,P=0.086),PFS 延长(8.90 vs 3.20 个月,P=0.459)。
  • PD-L1 状态与治疗对 PFS 无显著交互作用,无论 PD-L1 状态如何,两臂间 ORR、PFS 或 OS 均无显著差异。
  • STEPP 分析中,低复合风险患者较高复合风险患者获得更大的 PFS 绝对获益。

关键数值与推荐

  • HR 缺陷患者 GP 组 ORR 71.9% vs GT 组 38.7%(P=0.008),中位 PFS 10.37 vs 4.30 个月(P=0.011)。
  • gBRCA1/2 突变患者 GP 组 ORR 83.3% vs GT 组 37.5%(P=0.086),中位 PFS 8.90 vs 3.20 个月(P=0.459)。
  • 总体人群中 GP 组中位 PFS 7.73 个月(95%CI 6.46-9.00)vs GT 组 6.07 个月(95%CI 5.32-6.83),P=0.005。

临床怎么用

  • 对于 mTNBC 患者,GP 方案可作为一线化疗选择,尤其 HR 缺陷(含 gBRCA1/2 突变)患者可能从顺铂为基础方案中获益更多。
  • PD-L1 状态不宜用于筛选 GP 方案获益人群。
  • 复合风险模型有望辅助选择适合 GP 治疗的 TNBC 患者。

局限性

  • 胚系 HR 面板和 PD-L1 评估仅在部分患者中进行(分别为 55.9% 和 48.3%),可能存在选择偏倚。
  • gBRCA1/2 突变亚组样本量小,ORR 和 PFS 差异未达统计学显著性。
  • 复合风险模型为探索性分析,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CBCSG006 trial reported the superior efficacy of cisplatin plus gemcitabine (GP) regimen than paclitaxel plus gemcitabine (GT) regimen as first-line treatment of metastatic triple-negative breast cancer (mTNBC). This study focused on the updated survival data and the explorations of potential biomarkers for efficacy. PATIENTS AND METHODS: Germ-line mutations of homologous recombination (HR) panel, BRCA1/2 included, were evaluated in 55.9% (132/236) patients. PD-L1 expression was evaluated in 48.3% (114/236) patients. A nonparametric sliding-window subpopulation treatment effect pattern plot (STEPP) methodology was used to analyze the absolute survival benefits. All statistical tests were two-sided. RESULTS: Median progression-free survival (PFS) was 7.73 [95% confidence interval (CI) 6.46-9.00] months for GP arm and 6.07 (95% CI 5.32-6.83) months for GT arm (P = 0.005). No significant difference in overall survival (OS) was observed. There was significant interaction between HR status and treatment for PFS and status of HR deficient significantly correlated with higher objective response rate (ORR) and longer PFS in GP arm than in GT arm (71.9% versus 38.7%, P = 0.008; 10.37 versus 4.30 months, P = 0.011). There was no significant interaction between germ-line BRCA1/2 (gBRCA1/2) status and treatment for PFS. Patients with gBRCA1/2 mutation had numerically higher ORR and prolonged PFS in GP arm than in GT arm (83.3% versus 37.5%, P = 0.086; 8.90 versus 3.20 months, P = 0.459). There was no significant interaction between PD-L1 status and treatment for PFS, and no significant differences in ORR, PFS or OS between two arms regardless of PD-L1 status. In STEPP analysis, patients with lower composite risks had more absolute benefits in PFS than those with higher composite risks. CONCLUSIONS: GP regimen has superior efficacy than GT regimen as first-line chemotherapy for mTNBC patients. Germ-line mutations of BRCA1/2 and HR panel are possible biomarkers for better performance of cisplatin-based regimens. A composite risk model was developed to guide patient selection for GP treatment in TNBC patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01287624.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Lin Y, Sun XJ, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol. 2018. PMID: 29905759. doi:10.1093/annonc/mdy209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。